| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454683 | Lung Cancer | 2016 | 30 Pages |
Abstract
The results of this real-life cohort study like those of previous phase III/IV subgroups study analyses indicate that erlotinib is a valuable option for second-line treatment of stage IIIB/IV squamous NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Isabelle Monnet, Clarisse Audigier-Valette, Nicolas Girard, Alain Vergnenègre, Olivier Molinier, Pierre Jean Souquet, François Blanchon, Franck Bonnetain, Naila Taguieva-Pioger, Corinne Lamour, Marie Wislez,